{"id":1309,"date":"2004-01-01T12:04:00","date_gmt":"2004-01-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/effekte-einer-kombination-von-alpha-blocker-und-finasterid-bei-benigner-prostata-hyperplasie-bph"},"modified":"2004-01-01T12:04:00","modified_gmt":"2004-01-01T11:04:00","slug":"effekte-einer-kombination-von-alpha-blocker-und-finasterid-bei-benigner-prostata-hyperplasie-bph","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/effekte-einer-kombination-von-alpha-blocker-und-finasterid-bei-benigner-prostata-hyperplasie-bph","title":{"rendered":"Effekte einer Kombination von Alpha-Blocker und Finasterid bei Benigner Prostata-Hyperplasie (BPH)"},"content":{"rendered":"<p>Adrenerge Alpha-1-Rezeptor-Blocker (Tamsulosin = Alna\u00ae, Omnic\u00ae, Doxazosin, Alfuzosin = Urion\u00ae, Uroxatral\u00ae, Terazosin = Flotrin\u00ae, Terazoflo\u00ae) bessern die Beschwerden bei BPH schnell, verhindern jedoch nicht das allm\u00e4hliche weitere Wachstum der hyperplasierten Prostata. Der 5-Alpha-Reduktase-Hemmer Finasterid (Proscar\u00ae) f\u00fchrt zu einer ca. 20%igen Gr\u00f6\u00dfenreduktion der BPH, ist besonders bei einer Prostata-Gr\u00f6\u00dfe von > 40 ml indiziert und f\u00fchrt [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adrenerge Alpha-1-Rezeptor-Blocker (Tamsulosin = Alna\u00ae, Omnic\u00ae, Doxazosin, Alfuzosin = Urion\u00ae, Uroxatral\u00ae, Terazosin = Flotrin\u00ae, Terazoflo\u00ae) bessern die Beschwerden bei BPH schnell, verhindern jedoch nicht das allm\u00e4hliche weitere Wachstum der hyperplasierten Prostata. Der 5-Alpha-Reduktase-Hemmer Finasterid (Proscar\u00ae) f\u00fchrt zu einer ca. 20%igen Gr\u00f6\u00dfenreduktion der BPH, ist besonders bei einer Prostata-Gr\u00f6\u00dfe von > 40 ml indiziert und f\u00fchrt [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3182,398,1474,3183,1090,380,1734],"class_list":["post-1309","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alfuzosin","tag-doxazosin","tag-finasterid","tag-mtops-studie","tag-prostatahyperplasie","tag-tamsulosin","tag-terazosin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1309"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1309\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}